Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Purple Biotech (PPBT) Non-Current Assets (2016 - 2025)

Purple Biotech has reported Non-Current Assets over the past 7 years, most recently at $21.4 million for Q4 2022.

  • Quarterly Non-Current Assets fell 1.65% to $21.4 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $21.4 million through Dec 2022, down 1.65% year-over-year, with the annual reading at $21.4 million for FY2022, 1.65% down from the prior year.
  • Non-Current Assets was $21.4 million for Q4 2022 at Purple Biotech, down from $24.2 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $26.5 million in Q2 2021 and troughed at $9000.0 in Q4 2018.
  • The 5-year median for Non-Current Assets is $21.5 million (2021), against an average of $14.3 million.
  • Year-over-year, Non-Current Assets tumbled 99.85% in 2018 and then skyrocketed 135681.25% in 2021.
  • A 5-year view of Non-Current Assets shows it stood at $9000.0 in 2018, then skyrocketed by 166.67% to $24000.0 in 2019, then tumbled by 33.33% to $16000.0 in 2020, then skyrocketed by 135681.25% to $21.7 million in 2021, then fell by 1.65% to $21.4 million in 2022.
  • Per Business Quant, the three most recent readings for PPBT's Non-Current Assets are $21.4 million (Q4 2022), $24.2 million (Q3 2022), and $24.3 million (Q2 2022).